Tesofensine was impressively effective in this trial producing mean placebo-subtracted decreases in bodyweight of 4.5 kg (2.5%), 9.1 kg (7.2%) and 10.6 kg (8.6%) with once daily doses of 0.25 mg, 0.5 mg and 1.0 mg, respectively (Astrup et al., 2008b). These reductions were accompanied by decreases in body fat and waist circumference and also ...

Combination tesofensine and metoprolol in Prader-Willi syndrome. The FDA granted orphan drug designation for fixed-dose combination of tesofensine and metoprolol in PWS in March 2021 and hypothalamic obesity in July 2021. Tesofensine is a centrally acting monoamine reuptake inhibitor that blocks the presynaptic reuptake of dopamine, serotonin ...

2012年7月17日 · Tesofensine inhibits the presynaptic transporter of norepinephrine, dopamine and serotonin, thus increasing their availability [86]. It reverses low dopamine levels in nucleus accumbens and prefrontal cortex and increases dopamine transporter binding capacity in dorsal striatum, which might account for the reduced food intake and body weight in ...

2013年9月1日 · Tesofensine is a triple monoamine reuptake inhibitor which inhibits noradrenaline, 5-HT and dopamine reuptake. Tesofensine is currently in clinical development for the treatment of obesity, however, the pharmacological basis for its strong and sustained effects in obesity management is not clarified.

2014年2月1日 · Tesofensine (TE; NS2330) is a novel triple monoamine re-uptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA), norepinephrine (NE), and serotonin (5-HT), and with potentials as an anti-obesity agent (Astrup et al., 2008a, Astrup et al., 2008b).

2009年6月8日 · Tesofensine is a compound originally developed for the treatment of neurological diseases such as Alzheimer's and Parkinson's. However, it was found to cause significant weight loss during clinical trials in Parkinson's disease, leading to its current development for the treatment of obesity and type 2 diabetes.

2008年11月29日 · Tesofensine 0·25 mg and 0·50 mg had no effect on blood pressure, whereas tesofensine 1·0 mg significantly increased systolic and diastolic blood pressure (table 3). Furthermore, tesofensine had a dose-related effect on heart rate (table 3). Neither sex nor age was a significant covariate in any of the above effect measures (data not shown).

2018年2月9日 · Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity.[1] Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.[2]

2012年4月1日 · Tesofensine inhibits the presynaptic transporter of norepinephrine, dopamine and serotonin, thus increasing their availability [86]. It reverses low dopamine levels in nucleus accumbens and prefrontal cortex and increases dopamine transporter binding capacity in dorsal striatum, which might account for the reduced food intake and body weight in ...

2010年6月25日 · The sibutramine-treated DIO rats showed an initially more pronounced reduction in daily food intake as compared to tesofensine and rimonabant, however, the stronger anorectic effect of sibutramine was only observed during the first days of treatment (compared to tesofensine 1 mg/kg, days 1–4, P < 0.001; 2.5 mg/kg, days 1–3, P < 0.001 ...